Johnson & Johnson $JNJ Shares Sold by SCS Capital Management LLC

SCS Capital Management LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.6% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 161,365 shares of the company’s stock after selling 4,300 shares during the period. SCS Capital Management LLC’s holdings in Johnson & Johnson were worth $33,394,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in JNJ. Norges Bank acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $6,924,523,000. Vanguard Group Inc. increased its position in shares of Johnson & Johnson by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock worth $49,740,362,000 after purchasing an additional 3,731,074 shares in the last quarter. Capital International Investors increased its position in shares of Johnson & Johnson by 545.6% during the third quarter. Capital International Investors now owns 3,865,050 shares of the company’s stock worth $716,657,000 after purchasing an additional 3,266,354 shares in the last quarter. Amundi increased its position in shares of Johnson & Johnson by 19.3% during the third quarter. Amundi now owns 13,354,936 shares of the company’s stock worth $2,512,719,000 after purchasing an additional 2,163,838 shares in the last quarter. Finally, Marshall Wace LLP increased its position in shares of Johnson & Johnson by 126.3% during the third quarter. Marshall Wace LLP now owns 3,584,162 shares of the company’s stock worth $664,575,000 after purchasing an additional 2,000,609 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Down 0.1%

Shares of NYSE:JNJ opened at $225.16 on Monday. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. The business has a fifty day moving average of $233.02 and a two-hundred day moving average of $225.07. The stock has a market cap of $542.01 billion, a P/E ratio of 26.03, a PEG ratio of 2.21 and a beta of 0.26. Johnson & Johnson has a 52-week low of $149.04 and a 52-week high of $251.71.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.02. The company had revenue of $24.06 billion during the quarter, compared to analysts’ expectations of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm’s quarterly revenue was up 9.9% on a year-over-year basis. During the same period in the prior year, the business earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, research analysts expect that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be issued a $1.34 dividend. This represents a $5.36 annualized dividend and a yield of 2.4%. The ex-dividend date is Tuesday, May 26th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s dividend payout ratio (DPR) is currently 61.97%.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: J&J reported strong Phase 3 results for Erleada (apalutamide) in prostate cancer. The PROTEUS study met both primary endpoints, showing a lower risk of metastasis or death and a much higher likelihood of little to no cancer remaining after surgery, which could expand the drug’s role and support future oncology sales. Article: J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study
• Positive Sentiment: RYBREVANT FASPRO showed durable responses in advanced head and neck cancer in the OrigAMI-4 study, including a 42% confirmed response rate and complete responses in more than one-third of responders. J&J also submitted the therapy to the FDA for approval in this setting, adding another potential growth driver if the label is expanded. Article: RYBREVANT FASPRO pivotal data show strong and durable responses in advanced head and neck cancer
• Positive Sentiment: Several pieces highlighted J&J as a strong dividend stock, reinforcing its appeal as a low-beta, income-oriented healthcare name for investors seeking stability. Article: Is Johnson & Johnson one of the best dividend paying stocks to buy right now?
• Neutral Sentiment: A market recap article noted that JNJ stock was down 2.4% and questioned whether it is time to sell, but it did not provide a new company-specific catalyst beyond the recent move. Article: Johnson & Johnson stock price down 2.4% – time to sell?

Wall Street Analysts Forecast Growth

JNJ has been the subject of several research reports. Sanford C. Bernstein boosted their price target on Johnson & Johnson from $225.00 to $251.00 and gave the stock a “market perform” rating in a research report on Wednesday, April 15th. Leerink Partners upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price target for the company in a research report on Wednesday, May 13th. The Goldman Sachs Group boosted their price target on Johnson & Johnson from $265.00 to $275.00 and gave the stock a “buy” rating in a research report on Wednesday, April 15th. JPMorgan Chase & Co. boosted their price target on Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 15th. Finally, HSBC boosted their price target on Johnson & Johnson from $265.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. Twenty investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $253.04.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.